

BAB 5

KESIMPULAN DAN SARAN

5.1 Kesimpulan

Berdasarkan hasil studi literatur terhadap 10 jurnal mengenai penggunaan antiplatelet pada pasien stroke iskemik, dapat disimpulkan bahwa:

1. Pola penggunaan antiplatelet yang paling banyak adalah tunggal: aspirin (1 x 100 mg) po dan clopidogrel (1x75 mg) po, sedangkan kombinasi adalah: aspirin (1 x 80-100 mg) po + clopidogrel (1x75 mg) po, serta aspirin (1 x 100 mg) po + tikagrelor (2 x 90 mg) po dan telah sesuai dengan *guideline AHA/ASA 2018*.
2. Efektivitas aspirin ditunjukkan penurunan induksi asam arakidonat rata-rata sebesar 85,80%, penurunan induksi adenosin difosfat rata-rata sebesar 29,84%, clopidogrel ditunjukkan penurunan PT rata-rata sebesar 12,23%, aPTT rata-rata sebesar 14,69%, kombinasi aspirin + clopidogrel ditunjukkan penurunan PT rata-rata sebesar 8,31%, aPTT rata-rata sebesar 8,03% dan ditunjukkan penurunan induksi asam arakidonat sebesar 83,52% dan penurunan induksi adenosin difosfat sebesar 45,66%, juga aspirin + clopidogrel ditunjukkan penurunan inhibitor P2Y12 rata-rata sebesar 41,63%, kombinasi aspirin + cilostazol ditunjukkan penurunan induksi asam arakidonat sebesar 95,61%, penurunan induksi adenosin difosfat sebesar 43,69% dan aspirin + tikagrelor ditunjukkan penurunan inhibitor P2Y12 rata-rata sebesar 64,67%.

5.2 Saran

1. Perlu dilaksanakan kajian literatur dengan memperluas *database* yang digunakan sehingga jurnal yang digunakan semakin banyak agar dapat melakukan kajian secara lebih luas dan mendalam.
2. Untuk penelitian selanjutnya disarankan dilakukan penelitian mengenai efektivitas penggunaan antiplatelet pada pasien stroke iskemik dengan kombinasi aspirin-tikagrelor dengan menggunakan parameter yang tepat.

DAFTAR PUSTAKA

- American Society of Health-System Pharmacist (AHFS), 2011, *AHFS Drug Information Essentials*, American Society of Health-System Pharmacists, Bethesda, Maryland.
- Awtry, E.H. and Lascalzo, J., 2000, Aspirin, *circulation*, **101**: 1206-1218.
- Barlas, R. S., Loke, Y. K., Mamas, M. A., Bettencourt-Silva, J. H., Ford, I., Clark, A. B., Bowles, K. M., Metcalf, A. K., Potter, J. F. and Myint, P. K., 2018, Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke, *The American Journal of Cardiology*, **122(6)**: 1085-1090.
- Bijak, M. and Saluk-Bijak, J. 2017, Flavonolignans Inhibit the Arachidonic Acid Pathway in Blood Platelets, *BioMed Central Complementary and Alternative Medicine*, **17**: 396.
- Cha, J.K., Park, H.S., Nah, H.W., Kim, D.H., Kang, M.J., Choi, J.H., Huh, J.T. and Suh, H.K., 2016, High Residual Platelet Reactivity (HRPR) for Adenosine Diphosphate (ADP) Stimuli is a Determinant Factor for Long-term Outcomes in Acute Ischemic Stroke with Antiplatelet Agents: The Meaning of HRPR after ADP might be More Prominent in Large Atherosclerotic Infarction than Other Subtypes of AIS, *Journal Thrombolysis*, **42(1)**: 10-17.
- Dipiro, J. T., Dipiro, C. V., Wells, B. G. and Sewinghammer T. L. 2015, *Pharmacotherapy Handbook 9th Edition*, The McGraw-Hills Companies, New York.
- Dipiro, J. T., Yee, G. C., Posey, M. L., Haines, S. T., Nolin, T. D. and Ellingrod, V. 2020, *Pharmacotherapy: A Pathophysiologic Approach 11th Edition*, The McGraw-Hills Companies, New York.
- Fuadi, M. I., Nugraha, D. P. dan Bebasari, E., 2020, Gambaran Obesitas pada Pasien Stroke Akut di Rumah Sakit Umum Daerah Arifin Achmad Provinsi Riau Periode Januari-Desember 2019, *Jurnal Kedokteran Syiah Kuala*, **20(1)**: 13-17.
- Girotra, T., Lowe, F., Feng, W. and Ovbiagele, B. 2018, Antiplatelet Agents in Secondary Stroke Prevention: Selection, Timing, and Dose, *Curr Treat Options Neurol*, **20(8)**: 32.

- Himaja, J. and Rakesh, B. 2017, A Study of Clinical Profile, Risk Factors and Drug Utilization Pattern in Cerebrovascular Stroke, *European Journal of Biomedical and Pharmaceutical Sciences*, **4(1)**: 258-273.
- Hou, Y., Carrim, N., Wang, Y., Gallant, R. G., Marshall, A. and Ni, H. 2015, Platelets in Hemostasis and Thrombosis: Novel Mechanisms of Fibrinogen-Independent Platelet Aggregation and Fibronectin-Mediated Protein Wave of Hemostasis, *The Journal of Biomedical Research*, **29(6)**: 437-444.
- Inayah, N., Manggau, M. A. dan Amran, Y. 2018, Analisis Efektivitas dan Efek Samping Penggunaan Clopidogrel Tunggal dan Kombinasi Clopidogrel-Aspilet pada Pasien Stroke Iskemik di RSUP Dr. Wahidin Sudirohusodo Makassar, *Majalah Farmasi dan Farmakologi*, **22(3)**: 81-84.
- Jiang, X.L., Samant, S., Lesko, L.J. and Schmidt, S., 2015, Clinical Pharmacokinetics and Pharmacodynamics of Clopidogrel, *Clinical Pharmacokinetics*, **54(2)**: 147-166.
- Kapil, N., Datta Y. H., Alakbarova N., Bershad E., Selim M., Liebeskind D. S., Bachour O., Rao G. H. R. and Divani A. A. 2017, Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke, *Clinical and Applied Thrombosis/Hemostasis*, **23(4)**:301-318.
- Karishma, S., Reddy, D. R. B., Kumar, B. N., Babu, K. M., Sri, K. S. and Sneha, S. 2020, Assessment of Risk Factors and Drug Utilization Pattern of Stroke Patients in Neurology Department, *World Journal of Current Medical and Pharmaceutical Research*, **2(1)**: 53-62.
- Kementrian Kesehatan RI, 2018, *Riset Kesehatan Dasar*, Jakarta: Badan Penelitian dan Pengembangan Kesehatan.
- Koessler, J., Schwarz, M., Weber, K., Etzel, J., Koessler A., Boeck, M. and Kobsar, A., 2017, The Role of Adenosine Disphosphate Mediated Platelet Responsiveness for the Stability of Platelet Integrity in Citrated Whole Blood under ex vivo Conditions, *Plos One*, **12(11)**: e0188193.
- Kuriakose, D. and Xiaoa, Z. 2020, Pathophysiology and Treatment of Stroke: Present Status and Future Perspectives, *International Journal of Molecular sciences*, **21(20)**: 7609.
- Lukas S. dan Pravita A. 2020, Perbandingan Efektivitas Penggunaan Obat Antiplatelet Clopidogrel dan Kombinasi Clopidogrel dengan Aspilet

- pada Pasien Stroke Iskemik di RSUD Kab.Bekasi, *Social Clinical Pharmacy Indonesia Journal*, **5(1)**: 1-8.
- Meadows, T. A. and Bhatt, D. L. 2007, Clinical Aspects of Platelet Inhibitors and Thrombus Formation, *Circulation Research*, **100**: 1261-1275.
- Musuka, T. D., Wilton , S. B., Traboulsi, M. and Hill, M. D. 2015, Diagnosis and Management of Acute Ischemic Stroke: Speed is Critical, *Canadian Medical Association Journal*, **187(12)**: 887-893.
- Mutiarasari, D. 2019, Ischemic Stroke: Symptoms, Risk Factor, and Prevention, *Jurnal Ilmiah Kedokteran*, **6(1)**: 60-73.
- Nylander, S. and Schulz, R. 2015, Effects of P2Y12 Receptor Antagonists beyond Platelet Inhibition—Comparison of Ticagrelor with Thienopyridines, *British Journal of Pharmacology*, **173**: 1163-1178.
- Ohnuki, Y., Ohnuki, Y., Kohara, S., Shimizu, M. and Takizawa, S. 2017, Dual Therapy with Aspirin and Cilostazol may Improve Platelet Aggregation in Noncardioembolic Stroke Patients: A Pilot Study, *Internal Medicine*, **56**: 1307-1313.
- Ojaghaghghi, S., Vahdati, S. S., Mikaeilpour, A. and Ramouz, A. 2017, Comparison of Neurological Clinical Manifestation in Patients with Hemorrhagic and Ischemic Stroke, *World Journal of Emergency Medicine*, **8(1)**: 34-38.
- Panuganti, K. K., Tadi, P. and Lui, F. 2021, *Transient Ischemic Attack*, StatPearls Publishing diakses pada 13 Desember 2021, https://www.ncbi.nlm.nih.gov/books/NBK459143/#_NBK459143_p_ubdet
- Parker, W. A.E. and Storey, R. F. 2016, Ticagrelor: Agonising Over its Mechanism of Action, *The American Society of Hematology*, **128(23)**: 2595-24897.
- Parmar, P. 2018, Stroke: Classification and Diagnosis, *Pharmaceutical Journal*, **10(1)**: 1-15.
- Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., Jauch, E. C., Kidwell, C. S., Leslie-Mazwi, T. M., Ovbiagele, B., Scott, P. A. Sheth, K. N., Southerland, A. M., Summers, D. V. and Tirschwell, D. L., 2018, 2018 Guidelines for the Early Management of Patients with Acute Ischemic Stroke: A

- Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association, *Stroke*, **49(3)**: e46-e110.
- Que, B. J. dan Afflen, Z. V. 2017, Stroke Iskemik Emboli dengan Transformasi Hemoragik, *Molucca Medica*, **10(1)**: 82-93.
- Ramdhani A., Ramdhani M. A. and Amin, A. S. 2016, Writing a Literature Review Research Paper: A Step-by-Step Approach, *International Journal of Basic and Applied Science*, **3(1)**: 47-56.
- Sanyasi, R. D. L. R. and Pinzon, R. T. 2018, Clinical Symptoms and Risk Factors Comparison of Ischemic and Hemorrhagic, *Jurnal Kedokteran dan Kesehatan Indonesia*, **9(3)**: 5-15.
- Sari, M. dan Asmendri. 2020, Penelitian Kepustakaan (*Library Research*) dalam Penelitian Pendidikan IPA, *Jurnal Penelitian Bidang IPA dan Pendidikan IPA*, **6(1)**: 41-53.
- Sutrisno, H. 2016, Trik-trik Penelusuran Artikel Jurnal Nasional dan Internasional Berbasis Lembaga Indeks Nasional dan Internasional, *Jurnal Nasional Bagi Guru-Guru Kimia SMA/SMK/MA*.
- Teng, R. 2015, Ticagrelor: Pharmacokinetic, Pharmacodynamic and Pharmacogenetics Profile: An Update, *Clinical Pharmacokinetics*, **54(2)**: 1125-1138.
- Tripodi, A., Lippi, G. And Plebani, M., 2016, How to Report Results of Prothrombin and Activated Partial Thromboplastin Time, *Clinical Chemistry and Laboratory Medicine*, **54(2)**: 215-222.
- Valis, M., Klimova, B., Novotny, M. and Herzog, R. 2021, Antiplatelet Therapy in the Secondary Prevention of Non-Cardioembolic Ischemic Stroke and Transient Ischemic Attack: A Mini-Review, *Frontiers in Neurology*, **12**:626106.
- Vidyanti, A. N., Chan, L., Lin, C. L., Muo, C. H., Chung Y. Hsu, C. Y., Chen, Y. C., Wu, D. and Hui, C. J. 2019, Aspirin Better than Clopidogrel on Major Adverse Cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study, *Plos One*, **14(8)**: 1-10.
- Wang, C., Yi, X., Zhang, B., Liao, D., Lin, J. and Chi, L., 2015, Clopidogrel plus Aspirin Prevents Early Neurologic Deterioration and Improves 6-Month Outcome in Patients with Acute Large Artery Atherosclerosis stroke, *Clinical and Applied Thrombosis/Hemostasis*, **21(5)**: 453-461.

- Wang, Y., Chen, W., Lin, Y., Meng, X., Chen, G., Wang, Z., Wu, J., Wang, D., Li, J., Cao, Y., Xu, Y., Zhang, G., Li, X., Pan, Y., Li, H., Zhao, X., Liu, L., Lin, J., Dong, K., Jing, J., Johnston, S. C., Wang, D. And Wang, Y., 2019, Ticagrelor plus Aspirin versus Clopidogrel plus Aspirin for Platelet Reactivity in Patients with Minor Stroke or Transient Ischaemic Attack: Open Label, Blinded Endpoint, Randomised Controlled Phase II Trial, *The British Medical Journal*, **6**: 365-376.
- Wijaya A. K., 2013, Patofisiologi Stroke Non-Hemoragik Akibat Trombus, *E-Jurnal Medika Udayana*, **2**: 52-66.
- Wis'iewski, A. and Filipksa, K., 2020, The Phenomenon of Clopidogrel High On-Treatment Platelet Reactivity in Ischemic Stroke Subjects: A Comprehensive Review, *International Journal of Molecular sciences*, **21 (17)**: 6408.
- Yang, Y., Chen, W., Meng, X., Liu, L., Wang, Y., Pan, Y. And Wang, Y., 2020, Impact of Smoking on Platelet Function of Ticagrelor versus Clopidogrel in Minor Stroke or Transient Ischaemic Attack, *European Journal of Neurology*, **27**: 833-840.
- Yang, Y., Chen, W., Pan, Y., Yan, H., Meng, X., Liu, L., Wang, Y. And Wang, Y., 2020, Effect Clopidogrel versus Clopidogrel on Platelet Reactivity Measured by Thrombelastography in Patients with Minor Stroke or TIA, *Aging*, **12(20)**: 20085-20094.
- Yip, S. and Benavente, O. 2011, Antiplatelet Agents for Stroke Prevention, *The American Society for Experimental NeuroTherapeutics*, **8**: 475-487.
- Yueniwati, Y., 2015, *Deteksi Dini Stroke Iskemik*, Universitas Brawijaya Press, Malang.
- Zhang, L., Hu, X., Zhu, J., Cai, X., Kong, Y., Wang, H., Diao, S., Zhao, H., Jiang, J., Wang, D., Zhang, Q., Qin, Y., Yue, W. and Fang, Q., 2017, Adequate Platelet Function Inhibition Confirmed by Two Inductive Agents Predicts Lower Recurrence of Ischemic Stroke/Transient Ischemic Attack, *Biomed Research International*, **2017**: 3504950.
- Zhou, M., Chen, W., Pan, Y., Lin, Y., Meng, X., Zhao, X., Liu, L., Lin, J., Li, H., Wang, Y. and Wang, Y., 2021, Antiplatelet Effect of Ticagrelor with Aspirin in Acute Minor Stroke and Transient Ischemic Attack Stratified by CYP2C19 Metabolizer Status: Subgroup analysis of the PRINCE Trial, *Aging*, **13(3)**: 3994-4006.